Aflibercept for neovascular age‐related macular degeneration
S Sarwar, E Clearfield, MK Soliman… - Cochrane Database …, 2016 - cochranelibrary.com
Cochrane Database of Systematic Reviews, 2016•cochranelibrary.com
Background Central vision loss caused by age‐related macular degeneration (AMD) is the
leading cause of blindness among the elderly in developed countries. Neovascular AMD is
characterized by choroidal neovascularization (CNV). Growth of new blood vessels in
patients with neovascular AMD is driven by a complex process that involves a signal protein
called vascular endothelial growth factor A (VEGF‐A). Anti‐VEGF drugs that block this
protein include ranibizumab, bevacizumab, and aflibercept. Objectives To assess and …
leading cause of blindness among the elderly in developed countries. Neovascular AMD is
characterized by choroidal neovascularization (CNV). Growth of new blood vessels in
patients with neovascular AMD is driven by a complex process that involves a signal protein
called vascular endothelial growth factor A (VEGF‐A). Anti‐VEGF drugs that block this
protein include ranibizumab, bevacizumab, and aflibercept. Objectives To assess and …
Background
Central vision loss caused by age‐related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called vascular endothelial growth factor A (VEGF‐A). Anti‐VEGF drugs that block this protein include ranibizumab, bevacizumab, and aflibercept.
Objectives
To assess and compare the effectiveness and safety of intravitreal injections of aflibercept versus ranibizumab, bevacizumab, or sham for treatment of patients with neovascular AMD.
cochranelibrary.com
